郦守国, 郭群煌, 郭瑞祥. 脑胶质母细胞瘤术后照射缩小靶区放疗方案的疗效[J]. 中国辐射卫生, 2022, 31(6): 746-749,755.
LI Shouguo, GUO Qunhuang, GUO Ruixiang. Efficacy of postoperative radiotherapy with reduced target volume in patients with glioblastoma multiforme. Chinese Journal of Radiological Health, 2022, 31(6): 746-749,755.
[1] Ostrom QT, Gittleman H, Stetson L, et al. Epidemiology of gliomas[M]//Raizer J, Parsa A. Current Understanding and Treatment of Gliomas. Cham: Springer, 2015: 1-14. DOI: 10.1007/978-3-319-12048-5_1. [2] Weller M, Wick W, Aldape K, et al. Glioma[J]. Nat Rev Dis Primers, 2015, 1: 15017. DOI: 10.1038/nrdp.2015.17 [3] Wirsching HG, Galanis E, Weller M. Glioblastoma[J]. Handb Clin Neurol, 2016, 134: 381-397. DOI: 10.1016/B978-0-12-802997-8.00023-2 [4] Grech N, Dalli T, Mizzi S, et al. Rising incidence of glioblastoma multiforme in a well-defined population[J]. Cureus, 2020, 12(5): e8195. DOI: 10.7759/cureus.8195 [5] Bi WL, Beroukhim R. Beating the odds: extreme long-term survival with glioblastoma[J]. Neuro Oncol, 2014, 16(9): 1159-1160. DOI: 10.1093/neuonc/nou166 [6] Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities[J]. Clin Transl Oncol, 2016, 18(11): 1062-1071. DOI: 10.1007/s12094-016-1497-x [7] Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review[J]. J Clin Neurosci, 2018, 54: 7-13. DOI: 10.1016/j.jocn.2018.05.002 [8] Nam JY, de Groot JF. Treatment of glioblastoma[J]. J Oncol Pract, 2017, 13(10): 629-638. DOI: 10.1200/JOP.2017.025536 [9] Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance[J]. Pharmacol Res, 2021, 171: 105780. DOI: 10.1016/j.phrs.2021.105780 [10] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J]. 中华医学杂志, 2016, 96(7): 485-509. DOI: 10.3760/cma.j.issn.0376-2491.2016.07.003. Expert Group of Guidelines for Diagnosis and Treatment of Glioma in the Central Nervous System in China[J]. Natl Med J Chin, 2016, 96(7): 485-509. DOI: 10.3760/cma.j.issn.0376-2491.2016.07.003. [11] 中华医学会放射肿瘤治疗学分会. 胶质瘤放疗中国专家共识(2017)[J]. 中华放射肿瘤学杂志,2018,27(2):123-131. DOI: 10.3760/cma.j.issn.1004-4221.2018.02.001 Subcommittee of Tumor Radiotherapeutics, Chinese Medical Association. Expert consensus of China on radiation therapy for gliomas in 2017[J]. Chin J Radiat Oncol, 2018, 27(2): 123-131. DOI: 10.3760/cma.j.issn.1004-4221.2018.02.001 [12] Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251. DOI: 10.1093/neuonc/noab106 [13] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996. DOI: 10.1056/NEJMoa043330 [14] 陈姣红, 李红燕. 三维适形放射治疗70岁以上老年食管癌临床观察[J]. 中国辐射卫生,2016,25(4):500-501. DOI: 10.13491/j.cnki.issn.1004-714X.2016.04.046 Chen JH, Li HY. Clinical observation on three dimensional conformal radiotherapy for elderly patients with esophageal carcinoma at ages of over years[J]. Chin J Radiol Health, 2016, 25(4): 500-501. DOI: 10.13491/j.cnki.issn.1004-714X.2016.04.046 [15] Louis DN, Perry A, Reifenberger G, et al. WHO classification and grading of tumors of the central nervous system[M]. Lyon: IARC Press, 2016: 12-13. [16] Frosina G. Improving control of high-grade glioma by ultra-hyper-fractionated radiotherapy[J]. J Neurosci Res, 2022, 100(4): 933-946. DOI: 10.1002/jnr.25030 [17] Frosina G, Fontana V, Verzola D, et al. Ultra-hyper-fractionated radiotherapy for high-grade gliomas[J]. J Neurosci Res, 2021, 99(12): 3182-3203. DOI: 10.1002/jnr.24929 [18] Chang EL, Akyurek S, Avalos T, et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma[J]. Int J Radiat Oncol Biol Phys, 2007, 68(1): 144-150. DOI: 10.1016/j.ijrobp.2006.12.009 [19] 罗学臣, 李雪南, 沙翔燕, 等. 基于锥形束CT研究头颈部肿瘤调强放射治疗的计划靶区外放边界[J]. 中国医学装备,2018,15(4):50-52. DOI: 10.3969/J.ISSN.1672-8270.2018.04.013 Luo XC, Li XN, Sha XY, et al. A study on the extended margin of planning target volume of intensity modulate radiotherapy for head and neck neoplasm base on CBCT[J]. Chin Med Equip, 2018, 15(4): 50-52. DOI: 10.3969/J.ISSN.1672-8270.2018.04.013 [20] Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study[J]. Cancer, 1983, 52(6): 997-1007. DOI: 10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2 [21] Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy[J]. J Clin Oncol, 2002, 20(6): 1635-1642. DOI: 10.1200/JCO.2002.20.6.1635 [22] Monjazeb AM, Ayala D, Jensen C, et al. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 743-748. DOI: 10.1016/j.ijrobp.2010.10.018 [23] Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol[J]. Int J Radiat Oncol Biol Phys, 2004, 60(3): 853-860. DOI: 10.1016/j.ijrobp.2004.04.011 [24] 余力, 刘宵雪, 闫朝阳, 等. 面向多模态MRI脑胶质瘤区域三维分割与生存期预测的级联U-Net网络[J]. 中国图象图形学报,2022,27(3):850-861. DOI: 10.11834/jig.210137 Yu L, Liu XX, Yan CY, et al. Brain glioma tumor segmentation and survival prediction from multi-modality MRIs via cascaded U-Net[J]. J Image Graphics, 2022, 27(3): 850-861. DOI: 10.11834/jig.210137
